dr. (Matthijs) M.M. Versteegh

Business director Erasmus University of Rotterdam

Location: institute for Medical Technology Assessment (iMTA)
Room: J 5-55
Telephone: +31 10 4089170
Email: versteegh@eshpm.eur.nl

Profile

Matthijs Versteegh, PhD (Utrecht, The Netherlands, 1984) is business director at the institute for Medical Technology Assessment (iMTA) at Erasmus University of Rotterdam. Matthijs holds an undergraduate in health sciences, and a master (cum laude) in science & technology studies (Maastricht University). He obtained his PhD in health economics on quantifying quality of life for economic evaluations of health from Erasmus University of Rotterdam. After completing his PhD, Matthijs worked for consultancy firm Ecorys (Dutch office) on projects for the European Commission (DG SANCO), the World Health Organisation (in Moldova and Kazakhstan), the World Bank (in India) and large regional variation studies for the Dutch board of Health…

- M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
- M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0[go to publisher's site]
- M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: http://dx.doi.org/10.1016/j.socscimed.2016.07.043[go to publisher's site]
- M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003[go to publisher's site]
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: http://dx.doi.org/10.1177/0272989X11427761
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: http://dx.doi.org/10.1016/j.jval.2011.12.003
- - M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
  - M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0[go to publisher's site]
  - M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: http://dx.doi.org/10.1016/j.socscimed.2016.07.043[go to publisher's site]
  - M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003[go to publisher's site]
  - M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: http://dx.doi.org/10.1177/0272989X11427761
  - M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: http://dx.doi.org/10.1016/j.jval.2011.12.003
- - - M. Canoy, A.L. Bredenoord, M. Verweij & M.M. Versteegh (2018). Welke patiënten worden de dupe? NRC Handelsblad (print).
    - M. Canoy, M.M. Versteegh, A.L. Bredenoord & M. Verweij (2018). De prijs van zorg op een goudschaaltje. Medisch Contact.
    - M.M. Versteegh (2017). Vaar niet op deernis voor enkelen bij duur medicijn. NRC Handelsblad (print). doi: https://www.nrc.nl/nieuws/2017/10/13/vaar-niet-op-deernis-voor-enkelen-bij-duur-medicijn-13485415-a1577207
  - - M. Gheorghe, R.J. Hoefman, M.M. Versteegh & J. van Exel (2018). Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0706-6
    - W.B.F. Brouwer, P.H.M. van Baal, N.J.A. van Exel & M.M. Versteegh (2018). When is it too expensive? Cost-effectiveness thresholds and health care decision-making. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1000-4
    - S. de Groot, W.K. Redekop, M.M. Versteegh, S. Sleijfer, E. Oosterwijk, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2018). Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Quality of Life Research. doi: 10.1371/journal.pone.0177364
    - I. Corro Ramos, M.M. Versteegh, J.M. Koenders, G.C. Linssen, J. Meeder & M.P.M.H. Rutten - van Molken (2017). Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health. doi: https://doi.org/10.1016/j.jval.2017.05.013[go to publisher's site]
    - M.F. Jonker, A.E. Attema, B. Donkers, E.A. Stolk & M.M. Versteegh (2017). Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment. Health Economics, 26 (12), 1534-1547. doi: http://dx.doi.org/10.1002/hec.3445[go to publisher's site]
    - M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0[go to publisher's site]
    - M.M. Versteegh, S. Knies & W.B.F. Brouwer (2016). From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. Pharmacoeconomics (Print), 34 (11), 1071-1074. doi: http://dx.doi.org/10.1007/s40273-016-0431-y[go to publisher's site]
    - M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: http://dx.doi.org/10.1016/j.socscimed.2016.07.043[go to publisher's site]
    - M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003[go to publisher's site]
    - D.T. Arnold, D. Rowen, M.M. Versteegh, A. Morley, C.E. Hooper & N.A. Maskell (2015). Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health and Quality of Life Outcomes, 13 (6). doi: 10.1186/s12955-014-0196-y
    - S. de Groot, A.J. Rijnsburger, M.M. Versteegh, J.M. Heymans, S. Kleijnen, W.K. Redekop & I. Verstijnen (2015). Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers. BMJ Open, 5::e007241. doi: http://dx.doi.org/10.1136/bmjopen-2014-007241[go to publisher's site]
    - R. Crott, M.M. Versteegh & C.A. de Uyl-de Groot (2013). An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Quality of Life Research, 22 (5), 1045-1054. doi: 10.1007/s11136-012-0220-9.[go to publisher's site]
    - M.M. Versteegh, A.E. Attema, M. Oppe, N. Devlin & E.A. Stolk (2013). Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. European Journal of Health Economics (HEPAC), 14 (1), 43-51. doi: http://dx.doi.org/10.1007/s10198-013-0507-y[go to publisher's site]
    - B.M.F. Janssen, M. Oppe, M.M. Versteegh & E.A. Stolk (2013). Introducing the composite time trade-off: a test of feasibility and face validity. The European Journal Of Health Economics, 14, 5-13. doi: http://dx.doi.org/10.1007/s10198-013-0503-2[go to publisher's site]
    - A.E. Attema, M.M. Versteegh, M. Oppe, W.B.F. Brouwer & E.A. Stolk (2013). LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS. Health Economics, 22 (4), 376-392. doi: http://dx.doi.org/10.1002/hec.2804[go to publisher's site]
    - A.E. Attema & M.M. Versteegh (2013). Would you rather be ill now, or later? Health Economics, 22 (12), 1496-1506. doi: http://dx.doi.org/10.1002/hec.2894[go to publisher's site]
    - A.E. Attema, Y. Edelaar-Peeters, M.M. Versteegh & E.A. Stolk (2013). Time trade-off: one methodology, different methods. European Journal of Health Economics (HEPAC), 14 (1), 53-64. doi: http://dx.doi.org/10.1007/s10198-013-0508-x[go to publisher's site]
    - M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: http://dx.doi.org/10.1177/0272989X11427761
    - M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. Uyl - de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32 (4), 554-568. doi: http://dx.doi.org/10.1177/0272989X11427761[go to publisher's site]
    - M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: http://dx.doi.org/10.1016/j.jval.2011.12.003
    - C. de Sonneville-Koedoot, M.M. Versteegh & J.S. Yaruss (2011). Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A-D). Journal of Fluency Disorders, 36, 222-230. doi: http://dx.doi.org/10.1016/j.jfludis.2011.03.002
    - M.M. Versteegh, D. Rowen, J.E. Brazier & E.A. Stolk (2010). Mapping onto EQ-5D for patients in poor health. Health and Quality of Life Outcomes, 8 (141), 1-26. doi: http://dx.doi.org/10.1186/1477-7525-8-141
- - M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
- - M.M. Versteegh (2014, april 10). Quality of Life in Economic Evaluations of Health. EUR (187 pag.) Prom./coprom.: prof.dr. W.B.F. Brouwer.
Business director
University
institute for Medical Technology Assessment (iMTA)
School
Erasmus University of Rotterdam
Country
Nederland
Telephone
+31 10 4089170
EuroQoL research foundation
Role
Member
Obtained Wage
no

Current facets (Pre-Master)

dr. (Matthijs) M.M. Versteegh

More information

Profile

Featured publications (6)

All publications (33)

Key publication (6)

Article (25)

Professional Publication (3)

Scholarly Publication (22)

Part of book - Chapter (1)

Doctoral thesis (1)

Present position

Business director

Other positions (1)

EuroQoL research foundation